ES2113376T3 - Conjugados de anticuerpos para tratamiento de enfermedades neoplasticas. - Google Patents

Conjugados de anticuerpos para tratamiento de enfermedades neoplasticas.

Info

Publication number
ES2113376T3
ES2113376T3 ES91909732T ES91909732T ES2113376T3 ES 2113376 T3 ES2113376 T3 ES 2113376T3 ES 91909732 T ES91909732 T ES 91909732T ES 91909732 T ES91909732 T ES 91909732T ES 2113376 T3 ES2113376 T3 ES 2113376T3
Authority
ES
Spain
Prior art keywords
treatment
antibody conjugates
neoplastic diseases
diseases
zme
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES91909732T
Other languages
English (en)
Inventor
Michael G Rosenblum
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Research Development Foundation
Original Assignee
Research Development Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Research Development Foundation filed Critical Research Development Foundation
Application granted granted Critical
Publication of ES2113376T3 publication Critical patent/ES2113376T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A61K47/6865—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from skin, nerves or brain cancer cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/44—Antibodies bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6817—Toxins
    • A61K47/6819—Plant toxins
    • A61K47/6821—Plant heterodimeric toxins, e.g. abrin or modeccin
    • A61K47/6823—Double chain ricin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Botany (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Apparatus For Radiation Diagnosis (AREA)
  • Magnetic Resonance Imaging Apparatus (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

SE PRESENTAN INMUNOCONJUGADOS DE UN ANTICUERPO PARA UN ANTIGENO ASOCIADO CON EL TUMOR MELANOMA 240 KD. INMUNOCONJUGADOS CITOTOXICOS TALES COMO EL CONJUGADO DEL ANTICUERPO ZME-018 SON UTILES PARA EL TRATAMIENTO DE ENFERMEDADES DE CELULAS PROLIFERATIVAS TALES COMO EL MELANOMA ASI COMO OTROS TUMORES QUE SOPORTAN EL ANTIGENO ZME-018. TAMBIEN SE PRESENTAN COMPUETOS DETECTABLEMENTE ETIQUETADOS PARA LA DIAGNOSIS DE TALES ENFERMEDADES.
ES91909732T 1990-04-19 1991-04-19 Conjugados de anticuerpos para tratamiento de enfermedades neoplasticas. Expired - Lifetime ES2113376T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US51092390A 1990-04-19 1990-04-19

Publications (1)

Publication Number Publication Date
ES2113376T3 true ES2113376T3 (es) 1998-05-01

Family

ID=24032743

Family Applications (1)

Application Number Title Priority Date Filing Date
ES91909732T Expired - Lifetime ES2113376T3 (es) 1990-04-19 1991-04-19 Conjugados de anticuerpos para tratamiento de enfermedades neoplasticas.

Country Status (23)

Country Link
US (1) US20050214307A1 (es)
EP (1) EP0525119B1 (es)
JP (1) JP3340127B2 (es)
KR (1) KR100212372B1 (es)
CN (1) CN1071579C (es)
AT (1) ATE164078T1 (es)
AU (1) AU650267B2 (es)
CA (1) CA2079902C (es)
DE (1) DE69129109T2 (es)
DK (1) DK0525119T3 (es)
ES (1) ES2113376T3 (es)
FI (1) FI104234B (es)
HK (1) HK1008418A1 (es)
IE (1) IE62496B1 (es)
IL (1) IL97776A (es)
NO (1) NO317485B1 (es)
NZ (1) NZ237688A (es)
PT (1) PT97423B (es)
RU (1) RU2119352C1 (es)
SA (1) SA91120208B1 (es)
TW (1) TW211573B (es)
WO (1) WO1991016071A1 (es)
ZA (1) ZA912490B (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6750329B1 (en) * 1989-05-05 2004-06-15 Research Development Foundation Antibody delivery system for biological response modifiers
US6787153B1 (en) 1991-06-28 2004-09-07 Mitsubishi Chemical Corporation Human monoclonal antibody specifically binding to surface antigen of cancer cell membrane
CA2072249C (en) * 1991-06-28 2003-06-17 Saiko Hosokawa Human monoclonal antibody specifically binding to surface antigen of cancer cell membrane
US5632982A (en) * 1994-06-07 1997-05-27 The Board Of Trustees Of The Leland Stanford Junior University Cytotoxic enhancement of TNF with copper
ZA200305980B (en) * 2001-02-12 2007-01-31 Res Dev Foundation Modified proteins, designer toxins, and methods of making thereof
EP1414471B1 (en) 2001-07-17 2012-06-13 Research Development Foundation Therapeutic agents comprising pro-apoptotic proteins
WO2003105761A2 (en) * 2002-06-12 2003-12-24 Research Development Foundation Immunotoxin as a therapeutic agent and uses thereof
ATE496066T1 (de) * 2002-10-25 2011-02-15 Us Gov Health & Human Serv Verfahren zur prävention von tumorrezidiven durch blockade von tgf-beta
AU2006210769A1 (en) * 2005-02-01 2006-08-10 Research Development Foundation BLyS fusion proteins for targeting BLyS receptor and methods for treatment of B-cell proliferative disorders
US20080267964A1 (en) * 2005-02-17 2008-10-30 Masaki Terabe Synergistic Effect of Tgf-Beta Blockade and Immunogenic Agents on Tumors
US20070297983A1 (en) * 2006-03-16 2007-12-27 Soldano Ferrone Inhibition of breast carcinoma stem cell growth and metastasis
SG11201407106XA (en) 2012-05-01 2014-11-27 Genentech Inc Anti-pmel17 antibodies and immunoconjugates
KR101641206B1 (ko) 2013-06-24 2016-07-22 에이비엘바이오 주식회사 안정성이 개선된 항체-약물 결합체 및 이의 용도
PL238187B1 (pl) * 2015-01-23 2021-07-19 Helix Biopharma Corp Koniugaty przeciwciało-ureaza dla celów terapeutycznych
US11458172B2 (en) 2017-09-08 2022-10-04 New Portal Limited Nucleic acid systems that enable bacteria to specifically target solid tumors via glucose-dependent viability
CN110455903A (zh) * 2018-05-07 2019-11-15 天士力生物医药股份有限公司 一种注射用重组人尿激酶原杂质分析的梯度电泳检测方法

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4263279A (en) * 1975-08-19 1981-04-21 Yeda Research & Development Co. Ltd Pharmaceutically active compositions containing adriamycin and daunomycin
FR2504010B1 (fr) * 1981-04-15 1985-10-25 Sanofi Sa Medicaments anticancereux contenant la chaine a de la ricine associee a un anticorps antimelanome et procede pour leur preparation
US4522918A (en) * 1981-12-15 1985-06-11 Jeffery Schlom Process for producing monoclonal antibodies reactive with human breast cancer
US4671958A (en) * 1982-03-09 1987-06-09 Cytogen Corporation Antibody conjugates for the delivery of compounds to target sites
FR2546756B1 (fr) * 1983-06-03 1985-11-29 Centre Nat Rech Scient Nouveaux derives immunostimulants, leur preparation et leur application comme medicament
US4894443A (en) * 1984-02-08 1990-01-16 Cetus Corporation Toxin conjugates
US4753894A (en) * 1984-02-08 1988-06-28 Cetus Corporation Monoclonal anti-human breast cancer antibodies
FR2566271B1 (fr) * 1984-06-20 1986-11-07 Sanofi Sa Nouveaux conjugues cytotoxiques utilisables en therapeutique et procede d'obtention
US4650674A (en) * 1984-07-05 1987-03-17 Genentech, Inc. Synergistic cytotoxic composition
US4590071A (en) * 1984-09-25 1986-05-20 Xoma Corporation Human melanoma specific immunotoxins
US4677064A (en) * 1984-11-09 1987-06-30 Cetus Corporation Human tumor necrosis factor
US5032521A (en) * 1984-12-05 1991-07-16 The Salk Institute For Biological Studies Monoclonal antibody specific for a mammary tumor cell surface antigen
US4888415A (en) * 1985-03-04 1989-12-19 Dana-Farber Cancer Institute, Inc. Gelonin immunotoxin
US6084073A (en) * 1985-03-25 2000-07-04 Chiron Corporation Recombinant ricin toxin
US4870163A (en) * 1985-08-29 1989-09-26 New York Blood Center, Inc. Preparation of pure human tumor necrosis factor and hybridomas producing monoclonal antibodies to human tumor necrosis factor
US4935233A (en) * 1985-12-02 1990-06-19 G. D. Searle And Company Covalently linked polypeptide cell modulators
US4962188A (en) * 1985-12-06 1990-10-09 Cetus Corporation Recombinant ricin toxin A chain conjugates
US4831122A (en) * 1986-01-09 1989-05-16 Regents Of The University Of Minnesota Radioimmunotoxins
US4894227A (en) * 1986-08-01 1990-01-16 Cetus Corporation Composition of immunotoxins with interleukin-2
US4946778A (en) * 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US4771128A (en) * 1986-10-10 1988-09-13 Cetus Corporation Method of purifying toxin conjugates using hydrophobic interaction chromatography
US5019368A (en) * 1989-02-23 1991-05-28 Cancer Biologics, Inc. Detection of necrotic malignant tissue and associated therapy
US4963354A (en) * 1987-01-21 1990-10-16 Genentech, Inc. Use of tumor necrosis factor (TNF) as an adjuvant
US4894225A (en) * 1987-03-02 1990-01-16 Cetus Corporation Combination therapy using antitumor immunotoxins with tumor necrosis factor
US4863726A (en) * 1987-05-29 1989-09-05 Cetus Corporation Combination therapy using immunotoxins with interleukin-2
US5017371A (en) * 1988-01-06 1991-05-21 Amarillo Cell Culture Company, Incorporated Method for reducing side effects of cancer therapy
WO1989006692A1 (en) * 1988-01-12 1989-07-27 Genentech, Inc. Method of treating tumor cells by inhibiting growth factor receptor function
IE62463B1 (en) * 1988-07-07 1995-02-08 Res Dev Foundation Immunoconjugates for cancer diagnosis and therapy
US5134075A (en) * 1989-02-17 1992-07-28 Oncogen Limited Partnership Monoclonal antibody to novel antigen associated with human tumors
IE63847B1 (en) * 1989-05-05 1995-06-14 Res Dev Foundation A novel antibody delivery system for biological response modifiers
US6750329B1 (en) * 1989-05-05 2004-06-15 Research Development Foundation Antibody delivery system for biological response modifiers
US6306626B1 (en) * 1990-04-27 2001-10-23 Research Development Foundation Anti-IgM monoclonal antibodies and methods of their use
IE912716A1 (en) * 1990-08-14 1992-02-26 Res Dev Foundation Protein Structure of the Plant Toxin Gelonin
US6099842A (en) * 1990-12-03 2000-08-08 The United States Of America As Represented By The Department Of Health And Human Services Recombinant immunotoxin composed of a single chain antibody reacting with the human transferrin receptor and diptheria toxin
CA2074825C (en) * 1990-12-14 2005-04-12 Daniel J. Capon Chimeric chains for receptor-associated signal transduction pathways
US5837491A (en) * 1991-11-04 1998-11-17 Xoma Corporation Polynucleotides encoding gelonin sequences
US5621083A (en) * 1991-11-04 1997-04-15 Xoma Corporation Immunotoxins comprising ribosome-inactivating proteins
US6599505B1 (en) * 1992-04-10 2003-07-29 Research Development Foundation Immunotoxins directed against CD33 related surface antigens
IL112372A (en) * 1994-02-07 2001-08-26 Res Dev Foundation Non-viral vector for the delivery of genetic information to cells
US5513296A (en) * 1994-06-08 1996-04-30 Holmes Products Corp. Air heater with angled PTC heaters producing diverging heated airflow
AU3548799A (en) * 1998-04-03 1999-10-25 Invitrogen Corporation Libraries of expressible gene sequences
DE50112965D1 (de) * 2000-04-22 2007-10-18 Pharmedartis Gmbh Apoptotika
ZA200305980B (en) * 2001-02-12 2007-01-31 Res Dev Foundation Modified proteins, designer toxins, and methods of making thereof
EP1414471B1 (en) * 2001-07-17 2012-06-13 Research Development Foundation Therapeutic agents comprising pro-apoptotic proteins
WO2003105761A2 (en) * 2002-06-12 2003-12-24 Research Development Foundation Immunotoxin as a therapeutic agent and uses thereof

Also Published As

Publication number Publication date
PT97423A (pt) 1992-01-31
PT97423B (pt) 1998-10-30
FI104234B1 (fi) 1999-12-15
ATE164078T1 (de) 1998-04-15
CA2079902A1 (en) 1991-10-20
SA91120208B1 (ar) 2006-03-01
AU650267B2 (en) 1994-06-16
DE69129109D1 (de) 1998-04-23
IE911122A1 (en) 1991-10-23
FI924605A0 (fi) 1992-10-12
EP0525119A1 (en) 1993-02-03
JPH06502617A (ja) 1994-03-24
ZA912490B (en) 1992-12-30
KR930700140A (ko) 1993-03-13
IL97776A0 (en) 1992-06-21
FI924605A (fi) 1992-10-12
EP0525119B1 (en) 1998-03-18
IL97776A (en) 2000-10-31
NZ237688A (en) 1993-01-27
NO924025D0 (no) 1992-10-16
WO1991016071A1 (en) 1991-10-31
IE62496B1 (en) 1995-02-08
RU2119352C1 (ru) 1998-09-27
JP3340127B2 (ja) 2002-11-05
CN1071579C (zh) 2001-09-26
CN1055879A (zh) 1991-11-06
DK0525119T3 (da) 1998-11-23
TW211573B (es) 1993-08-21
FI104234B (fi) 1999-12-15
CA2079902C (en) 2001-08-28
US20050214307A1 (en) 2005-09-29
KR100212372B1 (ko) 1999-08-02
HK1008418A1 (en) 1999-05-07
DE69129109T2 (de) 1998-07-02
NO317485B1 (no) 2004-11-08
EP0525119A4 (en) 1993-09-15
NO924025L (no) 1992-10-16
AU7892291A (en) 1991-11-11

Similar Documents

Publication Publication Date Title
ES2113376T3 (es) Conjugados de anticuerpos para tratamiento de enfermedades neoplasticas.
RU92016354A (ru) Композиция, способы лечения, способ предупреждения рецидива, способ усиления цитотоксической активности иммунотоксина, способ усиления цитотоксического действия конъюгата
ES544846A0 (es) Un procedimiento para preparar una composicion citotoxica
NO885199D0 (no) FremgangsmŸte for fremstilling av monoklonale antistoffkonjugater.
GR1000712B (el) Νεα αντισωματα που αντιδρουν με τα ανθρωπινα καρκινωματα.
BRPI0017590B8 (pt) conjugado de maitansinoide - anticorpo anti-erbb, e formulação farmacêutica
ATE383430T1 (de) Rekombinante antikörper und immunkonjugate gezielt auf cd22-tragende zellen und tumoren
EP0226419A3 (en) Anti-human ovarian cancer immunotoxins and methods of use thereof
NZ210867A (en) Tumour-specific monoclonal antibodies, production thereof and use
GB1446536A (en) Pharmaceutically active compositions
ES556684A0 (es) Un procedimiento para tratar celulas efectoras que tienen receptores de superficie para la region fc de un anticuerpo
ES2119738T3 (es) Profarmacos de etoposido de glicosilo, procedimiento para su preparacion y su aplicacion en combinacion con conjugados enzimaticos funcionalizados, especificos de tumores.
ES2121881T3 (es) Anticuerpos monoclonales anti-gangliosidos, su preparacion y su empleo como agente terapeutico de tumores.
FI895005A0 (fi) Immunotoxiner foer behandling och profylax av autoimmuna sjukdomar.
WO2004041307A3 (en) Compositions and methods for treating cancer using cytotoxic cd44 antibody immunoconjugates and radiotherapy
EA200100311A1 (ru) Бифункциональные антитела и их применение для прицельной доставки противоопухолевых средств
TWI265811B (en) Extended type 1 chain glycosphingolipids as tumor-associated antigens
PT100660A (pt) Compostos conjugados uteis para o tratamento de tumores gastrointestinais e composicoes farmaceuticas que os contem
NO951061L (no) Antistoffkonjugater med forbedrede egenskaper

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 525119

Country of ref document: ES